Stoke Therapeutics Inc

STOK remains in a Stage 4 decline with a series of lower highs and lower lows, reinforced by a recent support failure. The medium-term tradable side is bearish, and short-term price is extended below declining EMAs and oversold, making immediate selling unfavorable. The long-term uptrend remains intact, supporting secular strength. Given the unfavorable timing to chase further downside, deferred sell-side engagement (Trim) is appropriate under the momentum-oriented strategy.

• ↑Phase 3 EMPEROR enrolled 162 patients; interim median seizure reduction of 59–91% with minimal adverse events
• ↑Ended Q1 2026 with $411 M cash, supporting operations through potential late 2027/early 2028 U.S. launch
• ↓Reported Q1 2026 net loss of $38.3 M versus $26.4 M prior quarter driven by elevated R&D spend